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ABSTR ACT: Metastasis is the leading cause of breast cancer-associated deaths. Despite the significant improvement in current therapies in extending 
patient life, 30–40% of patients may eventually suffer from distant relapse and succumb to the disease. Consequently, a deeper understanding of the metas-
tasis biology is key to developing better treatment strategies and achieving long-lasting therapeutic efficacies against breast cancer. This review covers recent 
breakthroughs in the discovery of various metastatic traits that contribute to the metastasis cascade of breast cancer, which may provide novel avenues for 
therapeutic targeting.
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Introduction
Breast cancer is the most common cancer among females 
worldwide, with an incidence rate of over 1.6 million cases 
per year.1 Because of the significant advancements in diag-
nosis, therapy, and disease prevention over the past 50 
years, breast cancer, unlike many other lethal cancers, is 
now considered a manageable disease. The five-year sur-
vival rate is up to 99% if the tumors are diagnosed early, 
and many patients are free of the disease for their lifetime. 
However, we remain far from a world without breast can-
cer, as it causes more than 0.5 million deaths every year. 
Over 90% of these patients die of metastasis, which is when 
cancer cells depart from their tumors of origin, spread sys-
temically, and colonize at distant organs.2 These metasta-
sis lesions invade vital organs and deteriorate the patient’s 
health, forming multiple foci that are challenging to sur-
gically remove and developing resistance to the systematic 
therapies that are currently available. Consequently, com-
bating metastasis is of core importance in winning the war 
against breast cancer.
Genomic Landscape of Breast Cancer
A comprehensive portrait of the genomic makeup of breast 
cancer has now become available as a result of multiple high-
throughput profiling efforts.3–7 These genomic data provide 
novel insights on the etiology of breast cancer. Breast can-
cer is traditionally classified into three subtypes based on 
the receptor status of estrogen receptor (ER), progesterone 
receptor (PR), and oncogene ERBB2 (HER2), termed ER+, 
HER2+ (ER-/PR-/HER2+), and triple-negative (TN) 
(ER-/PR-/HER2-). These receptor subtypes have been fur-
ther refined into five intrinsic breast cancer subtypes based 
on a 50-gene expression classifier (PAM50).8 These distinct 
molecular subtypes differ in their disease progression, pat-
terns of metastatic spread, clinical prognosis, and response 
to therapy. Thus, they have important implications on patient 
stratification, treatment planning, and clinical management 
for breast cancer.9
ER+ tumors, also referred to as luminal (LUM) subtypes 
by expression subtyping, account for ~70% of breast cancer 
cases. These tumors typically express high levels of ER and 
PR, and show an ER-dependent growth phenotype. These 
tumors are sensitive to estrogen withdrawal and are treated 
by hormonal therapy.10 ER+ tumors can be further divided 
into LUM-A and LUM-B subtypes based on the PAM50 
classifier. LUM-B tumors tend to have higher tumor grades 
and poorer prognosis than the LUM-A tumors, and they are 
often also HER2+, Ki67+ (a cell proliferation marker), or PR 
low.4 The HER2 subtype, constituting 10–15% of all breast 
cancer cases, is driven by the receptor tyrosine kinase (RTK) 
oncogene ERBB2. These tumors are characterized by ERBB2 
gene amplification/overexpression and responsiveness to 
anti-HER2 therapy, and are managed with this treatment 
modality in the clinic. TN breast cancers (15–20%), often 
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equated to basal-like breast cancers by expression subtyping, 
represent the most aggressive breast tumors among the three 
subtypes. There is no targeted therapy currently available, and 
patients are mainly managed with cytotoxic chemotherapy. 
A further refined classifying method, based on consensus of 
copy number and expression patterns, has been proposed to 
divide breast cancer into 10 subtypes.5 The integration of this 
novel method with the established classification systems and 
its clinical significance remains to be further assessed.
Breast cancer has intermediate genomic alteration com-
plexity and global mutation frequency among all cancer 
types.11,12 ER+ tumors are the quietest in genome-wide alter-
ations among the three subtypes, but they harbor the most 
recurrently mutated genes, including activating mutations 
for PI3 kinase (PI3K) catalytic subunit PIK3CA and loss-of-
function mutations for tumor suppressor TP53, mammary 
lineage specifiers GATA3, FOXA1, p38/JNK1 stress pathway 
kinases MAP3K1 and MAP2K4, and cell adhesion molecule 
CDH1.4 Notably, the estrogen receptor gene ESR1 itself is 
rarely mutated or amplified in breast cancer.13–15 This raises an 
interesting question of whether ER overexpression is a driver 
event of ER+ tumor transformation. In normal breast, ER 
expression is restricted to a small subset of quiescent LUM 
cells within the mammary epithelium, whereas in cancerous 
lesions, elevated ER expression is detected in a large propor-
tion of proliferating cells.16 How ER expression is elevated in 
ER+ tumors remains poorly understood and needs to be fur-
ther investigated.17
HER2 subtype is dominated by ERBB2 amplification. 
A substantial proportion of these tumors also harbor TP53 
or PIK3CA mutations. Mutations in other genes are seen at 
a much lower frequency (such as PIK3R1, 4%).4 TN breast 
cancers, in contrast, are marked by the mutations in the tumor 
suppressor TP53 (up to 80%).3,4,18 Consistent with the loss of 
this gatekeeper in genomic integrity and DNA repair, TN 
breast tumors typically display more genomic chaos, enrich-
ment in BRCA1 mutation, and sensitivity to chemo reagents. 
No notable oncogene mutations are recognized in this sub-
type, except PIK3CA at a low frequency (9%). This is in line 
with the idea that heterologous oncogenic signaling may be 
able to drive tumorigenesis in this subtype and that TN breast 
cancer as a whole is a heterogeneous group.6 More refined sub-
groups perhaps exist within this subtype.5
A recurrent theme from these genomic characterizations 
is the activation of PI3K–Akt signaling, seen in all three breast 
cancer subtypes.4 In ER+ breast cancer, PIK3CA mutation 
itself accounts for 40% of cases. The rest of the cancers may 
reach PI3K–Akt activation through loss or downregulation 
of the negative regulators PTEN or INPP4B, through copy 
number amplification or overexpression of other RTKs such 
as IGF1R or FGFR, or through active ER signaling itself. 
In HER2+ breast cancer, PI3K–Akt activation is a major 
downstream event of ERBB2-initiated oncogenic signaling.19 
In TN breast cancer, even though PIK3CA mutation is seen 
at a low rate, the PI3K pathway activity inferred from gene 
expression or protein array signatures is actually the highest.4 
This pathway may be activated in these tumors through 
PIK3CA copy number gain, PTEN or INPP4B loss, EGFR 
amplification or overexpression, or AKT3 amplification. 
Viewed in this way, Akt activation seems to be a hallmark of 
breast cancer. Indeed, deregulated PI3K–Akt signaling also 
plays a pivotal role in many aspects of breast cancer metastasis 
(as discussed below).
It is important to note, however, that most of these 
genomic studies are based on primary tumors and not metas-
tasis samples. Thus, the amount of information one can deduce 
for metastasis biology and relate it to therapeutic intervention 
remains to be seen.
Metastatic Patterns of Breast Cancer
It is well known from clinical observations that different 
tumor types display distinct organ tropisms in metastatic 
patterns.20 Breast cancer displays distinct tropisms depend-
ing on the subtypes.21 Bone, lung, liver, and brain are the 
common target organs for breast cancer metastasis, in addi-
tion to distant lymph nodes. ER+ tumors have the best prog-
nosis with a low incidence rate within the first five years. But 
this rate gradually increases as the time extends beyond five 
years (up to 40%). Bone is the predominant metastatic site, 
whereas brain is much less affected. In contrast, TN breast 
tumors display the worst prognosis, with a spiking incidence 
rate within the first one to two years and virtually all metas-
tases occurring within the first five years.21,22 Visceral organs, 
including brain and lung, are more frequently affected in 
TN tumors. HER2+ tumors are also considered an aggres-
sive disease.21 With the invention of anti-HER2 therapy, 
the prognosis has been much improved and patient lifespan 
is significantly prolonged. The therapy is quite effective in 
controlling extracranial lesions but leave brain metastasis a 
remaining challenge.
What underlies the metastasis tropism has been a 
heated topic.23 The spreading pattern of blood flow can 
explain some tumor types. For example, the primary site of 
colon cancer metastasis is the liver and the second site is the 
lung. This is explained by the massive cell trapping in the 
liver capillary after mesenteric circulation and then in the 
lung after cancer cells come out of circulation from liver.2 
However, such an explanation is not likely to be applicable in 
the case of breast cancer. An alternative view to the circula-
tion pattern was first proposed by Paget in the 19th century, 
who posited that disseminated cancer cells (seeds) can form 
metastases as they reach a microenvironment (soil) that is 
congenial enough for their survival and proliferation.24 This 
seed-and-soil hypothesis25 has received extensive support 
with the identification of gene mediators that contribute to 
metastasis formation.26–33
Even though it remains unclear what determines the 
“seeds” will fit in a particular soil, some basic nature of the 
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breast cancer subtypes may shed light on their organ prefer-
ences. Bone is a major target site for ER+ breast cancer metas-
tasis. It is worth noting that bone is also rich in estrogen, 
which, in normal physiology, plays a critical role in the main-
tenance of bone homeostasis and remodeling.34 Therefore, 
ER+ tumor cells lodging in the bone marrow may have a par-
ticular advantage in hijacking the available estrogen for pro-
liferating signal. HER2+ tumors are driven by the ERBB2/
ERBB3 heterodimer in a ligand-independent manner and are 
self-sufficient for oncogenic signaling. This may give them a 
particular advantage for developing brain metastasis, because 
the brain has fewer immune cells compared to the rest of the 
body,35 and all it may require is self-sufficiency in proliferation. 
One may also speculate that the extensive metastatic potential 
and overall aggressiveness of the TN breast cancers are related 
to their high activity of PI3K–Akt signaling and cell viability, 
though this requires further experimental validation.
Metastasis Cascade
Cancer cells need to undergo a series of steps in order to depart 
from the primary site and spread to various organs. This metas-
tasis cascade36 comprises the steps of cancer cells: (1) becoming 
locally invasive and migratory, (2) reaching the blood vessel 
and intravasating into the circulation, (3) circulating via the 
blood flow, (4) arresting and extravasating to the distant organ, 
(5) surviving the initial hostile stress, and (6) reinitiating out-
growth and co-opting the distant stroma (Fig. 1).
To achieve each of these steps, cancer cells have to 
encounter multiple layers of natural barriers and challenge 
the defined organization and the established homeostasis of 
target organs.2 As a result, one could imagine that metastasis 
is an extraordinarily inefficient process. It is estimated that 
more than 99.98% of disseminated cancer cells die before a 
metastasis could form.23 However, early steps of metastasis, 
such as intravasation and extravasation, can occur surpris-
ingly more efficiently than expected. Tumors at early stages 
may already release cancer cells into circulation before signs 
of invasion.37 Experimental evidence showed that more than 
80% of inoculated cells succeed in extravasating.38 Even nor-
mal epithelial cells may have the ability to invade distant 
organs.39,40 Most attrition occurs after the extravasation step. 
Less than 3% of the cells can survive to form micrometasta-
ses and an even lower percent makes to proliferate and forms 
macro lesions.38,41 Thus, it is more and more recognized that 
survival and outgrowth in foreign tissue are the rate-limiting 
steps for metastasis colonization and constitute the bottleneck 
of the metastasis cascade.42
Local Invasion
To overcome the multiple organismal barriers, tumor cells 
have to gain an extra set of gene activities or characteristics, 
in addition to their ability to grow without restriction in the 
primary tumor. Epithelial-to-mesenchymal transition (EMT) 
governs the local invasion step of epithelial cancer.23 Tumor 
cell properties, such as becoming migratory and secreting 
extra cellular matrix (ECM)-destructing enzymes, are asso-
ciated with this program. EMT is controlled by a transcrip-
tional program comprising Twist, Slug, Snail, ZEB1, ZEB2, /RFDOLQYDVLRQ,QWUDYDVDWLRQ &LUFXODWLRQ ([WUDYDVDWLRQ6XUYLYDO'RUPDQF\2XWJURZWK3ULPDU\WXPRU 0HWDVWDVLV/RFDOLQYDVLRQ(07SURJ003V ,QWUDYDVDWLRQ(5(*003V37*6)6&1 &LUFXODWLRQ7UN%:17 6XUYLYDO$.7VLJ6UF9&$06HUSLQV 'RUPDQF\S(5.VLJ%03VLJ([WUDYDVDWLRQ(5(*+%(*)003V37*6)6&1$1*37/67*$/1$& 2XWJURZWKRVWHRO\WLFSURJ0(7SURJ:17VLJ127&+VLJ&;&/71&32671,'V
Figure 1. a schematic shows the metastasis cascade and the gene mediators, signaling pathways, and programs that contribute to each step of the cascade. 
Abbreviations: eMt, epithelial-to-mesenchymal transition; prog., program; sig., signaling.
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and miR-200s.43 These factors respond to external stimuli, 
such as TGFβ, WNT, or hypoxia, and act in concert to elicit 
changes in the surface molecule profiles, including loss of 
E-cadherin and gain of N-cadherin or vimentin,44 transition 
from CD44lowCD24high to CD44highCD24low,45 and expres-
sion of matrix metalloproteinases (MMPs).46 These traits col-
lectively lead cells to invade the surrounding stroma, reach the 
blood vessel, and intravasate into the circulation.
Circulation
To survive the transit in circulation, cancer cells need to resist 
anoikis, shear forces of the blood flow, and innate immune 
attack. Anoikis is a death stress for epithelial cells from anchor-
age detachment.47 It has been shown that circulating tumor 
cells (CTCs) overexpress TrkB or WNT2 to resist this form 
of death stimulus.48,49 CTCs also form clusters with platelets, 
termed emboli, to evade killing from shear forces as well as pre-
dation of natural killer (NK) cells.50 It is noteworthy, however, 
that circulation is a relatively quick process and cells may reach 
other organs within minutes after entering circulation.23,42 
This short period in transit may partially explain why the attri-
tion of cells during circulation is not significant.
Extravasation
Extravasation and intravasation are, to some degree, mirrored 
processes.2 Thus, genes contributing to intravasation steps 
may also participate in the extravasting process. Epiregulin 
(EREG), MMP-1, MMP-2, prostaglandin-endoperoxide 
synthase 2 (PTGS2, also called cyclooxygenase-2 (COX-2)), 
and fascin (FSCN) are genes involved in vessel remodeling 
and intravasation, and they also facilitate disruption of vascu-
lar junctions and let cancer cells invade into distant organs.51,52 
Moreover, the normal vascular organization of a distant organ 
may differ from that of primary tumors and require additional 
genes for penetrating distant tissues. The tight lung capillaries 
require the attainment of angiopoietin-like 4 (ANGPTL4) in 
cancer cells for the opening and leakage of pulmonary vessels.53 
The even tighter structure of blood–brain barriers, composed 
of endothelial cells, pericytes, and astrocytes, requires addi-
tional players such as α2,6-sialyltransferase (STGALNAC6) 
and heparin-binding epidermal growth factor (HB-EGF) for 
extravasating into the brain.28
Survival
After passing these steps, the disseminated tumor cells (DTCs) 
face the biggest hurdle toward their colonization, the foreign 
microenvironment.42 The differences in stromal components, 
tissue organization, matrix composition, and cytokine envi-
ronment all impose immense threats on the just arrived cancer 
cells. As a result, the limited prosurvival signal that cancer 
cells can grasp from surroundings may play a critical role in 
determining whether they can take a foothold. The genes 
required for survival in different sites also differ as the organ 
varies.36 When breast cancer cells lodge in the bone marrow, 
cancer cells take advantage of CXCL12 and IGF1 from the 
surrounding stroma to induce PI3K–Akt survival signaling.54 
Src amplifies the magnitude of this signaling and contributes 
to cancer cell survival in bone metastasis. In the case of lung 
metastasis, by bridging with macrophages, VCAM-1 in breast 
cancer cells elicits the activation of PI3K–Akt survival signal-
ing and confers cell fitness.55 In the brain, cancer cells protect 
themselves by secreting serpins, thus shielding themselves 
from being killed by the reactive brain stroma.56
Outgrowth
The surviving cancer cells then need to engage extra genes that 
could modify the distant stroma and extract signals that trig-
ger their intrinsic oncogenic signaling for proliferation. Bone 
is well investigated in this respect. Bone metastatic breast can-
cer cells express a set of pro-osteolytic genes to tip the intricate 
balance between osteoblasts and osteoclasts.57,58 These genes, 
whether working through osteoblasts (parathyroid hormone-
related protein (PTHrP), jagged1 (JAG1) or through osteo-
clasts (interleukin-8 (IL-8), interleukin-11 (IL-11), osteopontin 
(OPN), A disintegrin and metalloproteinase with thrombos-
pondin motifs 1 (ADAMTS1), MMP-1) lead to activation of 
the osteolytic cycle.29,59–61 The activated osteoclasts dissolve 
the bone matrix and let it release the growth factors depos-
ited within. These factors foster the cancer cell growth and 
exacerbate the feed-forward interaction between cancer cells 
and bone stromal cells, resulting in a vicious cycle and patient 
symptoms, including bone pain and fracture.62 In pulmonary 
metastasis, CXCL1 secreted by lung-disseminated cancer cells 
recruits myeloid progenitors, which in turn provides S100A/B 
for cancer cell proliferation.63 Such paracrine interactions 
are also evidenced between cancer cells and other resident or 
recruited stromal components, including macrophages and 
endothelial cells.64,65 Cancer cells engage the ECM proteins 
tenascin C (TN-C) and periostin (POSTN), either from 
their own source or from the surrounding stroma, to create a 
stem-like niche that potentiates WNT and NOTCH signal-
ing for growth in the lung.66,67 What program contributes to 
the propagation of brain metastases is less understood. Recent 
work suggests that juxtacrine interaction between cancer cells 
and astrocytes may provide such an advantage.68,69 The brain 
microenvironment may also elicit reprograming of cancer cells 
toward neuronal characteristics to adapt to the brain stroma.70
Collectively, completion of the metastasis cascade requires 
coordinated action of multiple gene programs, and distinct 
tissue microenvironments require distinct gene sets for organ-
specific colonization. These genes either overcome or com-
pensate for the incompatibilities between the intrinsic growth 
demands of the seeds and the extrinsic restrictions imposed by 
the particular foreign soil.
Evolution of Metastatic Traits
How metastatic traits arise as the primary tumor evolves 
remains a poorly investigated question.23,42,71 Identifying the 
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drivers of metastasis is of great interest, as they may be key 
targets for therapeutic intervention. Additionally, these driv-
ers may serve as indicators of metastatic risk that could play an 
important role in stratifying breast cancer patients for adju-
vant therapy. A clonal view of tumor evolution72 implicates 
that the genetic and epigenetic instabilities that are intrinsic 
to cancer cells generate sufficient diversity among the cancer 
cell population, upon which the selective pressure acts to fos-
ter the expansion of favorable clones. Such cycles of mutation 
and clonal selection drive the expansion of the fittest tumor 
cells and lead to the emergence of various traits in the tumor.73 
This Darwinian model is well exemplified by the sequential 
progression of colorectal cancer.74 The serial transition from 
a benign tissue to an adenoma and to an aggressive carci-
noma is a result of multiple waves of clonal expansion driven 
by mutations in APC, KRAS, PIK3CA, TP53, and TGFβ 
pathways.75,76 The study of these tumor drivers led to further 
speculation as to whether metastatic traits are also driven by 
additional mutations.76 Rare clones possessing such muta-
tions from primary sites may be selected and expanded as they 
spread and reach secondary sites.77 If these speculations were 
true, one would expect that the molecular determinants of 
metastasis would not be overtly manifested in the bulk pri-
mary tumor but be specific to metastases, because the distinct 
microenvironments of the distant organs and the primary sites 
impose different selective pressures on tumor cells. As a result, 
metastases and their primary tumors should be sufficiently 
different in both genomic composition and expression. How-
ever, pair-wise comparisons of primary tumors and metasta-
ses in multiple tumor types, including breast cancer, failed 
to find mutations that were private, specific, and recurrent to 
metastases.78–83 On the contrary, the identified genetic altera-
tions in metastases are also commonly shared by the primary 
tumor.42 Transcriptomic profiling of tumor and metastasis 
pairs also showed that the two lesions are more alike than 
different.84 Given that these findings need to be confirmed 
by larger scale studies, no driver mutations that are specific 
for metastasis have been identified to date. Furthermore, gene 
activities contributing to distant metastasis can already be 
detected in primary tumors. As an ensemble, they form gene 
signatures that predict the likelihood of metastasis and patient 
prognosis.28,30,31,53,54,85–88 As a result, the clonal view of tumor 
evolution seems to contradict the actual failure in identifying 
metastasis specific driver mutations. The Darwinian selection 
of rare clones also finds itself incompatible with the clinical 
observation of metastatic mediators being expressed in large 
segments of primary tumors. These apparent discrepancies 
lead to the conundrum as to how metastatic traits, especially 
those that are distant organ specific, could ever be evolved in 
the primary tumor.
These conceptual inconsistencies and confusions start 
to become solved by recent insights on the evolvement of 
metastatic traits in breast tumors. A case in point is Src 
activity in breast cancer cells, which is both a functional 
mediator and a prognostic indicator of bone metastasis in 
breast tumors.89 Querying how Src activity is enriched in 
tumors, three general principles emerge that may lead to the 
evolution of metastatic traits.
Oncogenically Encoded
As evidenced in ER+ breast tumors, in some cases, the meta-
static traits are encoded in the oncogenic signaling and are 
intrinsic to the tumor cell properties. ER signaling biochemi-
cally activates Src and directly confers ER+ tumor cells high 
Src activity.89 Src contributes to bone metastasis and promotes 
cancer cell survival by amplifying the magnitude of PI3K–
Akt signaling induced by CXCL12 and IGF1, the mesenchy-
mal cytokines from the bone marrow. Similarly, E-cadherin 
expressed on the surface of ER+ breast tumor cells forms 
heterotypic adherens junctions with N-cadherin in the osteo-
genic cells of the bone marrow and induces mTOR activation, 
a downstream effector of PI3K–Akt signal.90 Collectively, 
these bone metastatic traits arise with the oncogenic signaling 
and are intrinsically encoded in ER+ tumors.
Gene Repurposing
The second scenario, as exemplified in HER2+ tumors, is 
gene repurposing or gene re-exploitation. In primary tumors, 
Src facilitates ERBB2–ERBB3 heterodimerization and their 
kinase activation.89 Src is not essential for ERBB2-initi-
ated oncogenesis, but having it provides additional survival 
advantage. This explanation agrees well with the observation 
that ~50% of HER2+ breast tumors are Src active. Ampli-
fying the oncogenic signaling may not be critical for cancer 
cell growth in the primary tumor but may become critical and 
rate-limiting for survival when cells are threatened in the for-
eign bone marrow tissue. In similar ways, EREG, COX-2, 
MMP-1, and MMP-2 promote breast tumor growth via 
angiogenesis regeneration and vessel remodeling. These genes 
are reutilized for intravasation and extravasation purposes 
during metastasis.51 Genes normally involved in developmen-
tal programs or stemness maintenance may also be hijacked or 
reexploited for metastatic purposes. Indeed, if tumorigenesis 
is viewed as a process diverging from normal developmental 
regulation, cancer characteristics, including metastatic traits, 
are essentially a negotiation between the tumor-causing genes 
and the remaining normal genes. Melanomas are highly 
metastatic partly because of their neural crest origin, which is 
highly migratory in nature.91 On top of the oncogenic drivers, 
they may need few extra aberrations to metastasize.
EMT transcription factors, such as Slug and Sox9, main-
tain mammary stem cell states in normal contexts and medi-
ate long-term mammary gland reconstitution in mice.92 These 
genes in breast cancer are repurposed for mesenchymal and 
invasive phenotypes and contribute to the metastasis seed-
ing of cancer cells. A similar finding points at another EMT 
controller ZEB1 as a determinant of the so-called cancer-
stem-cell state.93 ELF594 and GATA3,95 normal regulators of 
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mammary gland alveologenesis and LUM specification, are 
found to restrain EMT and suppress metastasis of breast can-
cer. Inhibitors of differentiation such as ID1 and ID3, genes 
thought to lock cell state, confer tumor reinitiation capabilities 
and sustain cancer proliferation during early metastatic coloni-
zation. This occurs partly through mesenchymal-to-epithelial 
transition (MET).96,97 Thus, these normal genes may be partly 
active or repressed during tumorigenesis, and their remnant 
activities may serve as metastatic traits.
Stroma
The third principle is the contribution from tumor-associated 
stroma and the microenvironment they shape. Querying fea-
tures associated with Src activity enrichment that may explain 
the bone metastatic ability in the TN primary tumors failed 
to identify any biochemical links.89 This is in part consistent 
with the notion that TN breast cancer is a heterogeneous 
disease. Instead, the common feature shared by these Src-
positive tumors is an enriched mesenchymal stroma. The mes-
enchymal stroma in many respects, including the cytokine 
composition, resembles the mesenchymal niches in the bone 
marrow. Such a primary tumor microenvironment nurtures 
the expansion of cancer cell clones with high Src activity and 
skews the carcinoma population toward a preponderance of 
clones with a predisposition to grow in the bone marrow. As 
a result, the mesenchymal stroma serves as a driving force for 
the bone metastatic trait in TN breast tumors. Thus, simi-
larities between the microenvironment of primary tumors and 
that of the distant sites make the preselected metastatic seeds 
compatible with the target tissue and prime the development 
of organ-specific metastatic traits in primary tumors.
In addition to this example, it has been widely shown that 
different stromal components in primary tumors play critical 
roles in promoting tumor growth, increasing their invasive-
ness, and inducing the EMT phenotype.98 Fibroblasts, mac-
rophages, and myeloid progenitors also secrete molecular cues 
that maintain the stemness of the cancer cells at the invasive 
front.99 Certain stromal cells promote metastatic colonization 
in an organ-specific manner in distinction to those in the pri-
mary tumors.64,100 Systemic responses elicited by the primary 
tumors may also cause behavioral changes in stromal cells, 
which in turn affect metastatic spread.101–104 Indeed, stroma 
is a co-evolving feature with tumor evolution and has many 
implications on the metastatic properties of tumor cells.42
In summary, metastatic traits may arise from a combina-
tion of oncogenic forces, repurposing of intrinsic cellular prop-
erties, and stromal influences. An important lesson learned 
from the above findings is the relation of microenvironment 
similarity to the metastatic organ tropism. The distinction of 
distant sites from the primary sites has been long recognized 
and advocated.23,36 Even the best soil is still deadly overall for 
the disseminated cancer cells. Thus, what becomes critical is 
their chance to find a similar feature like their home from the 
vast sea of differences in the foreign tissue. Such a view is in line 
with Paget’s seed-and-soil theory24 and may help reveal new 
opportunities for therapeutic intervention against metastasis.
Targeting Metastasis
The identification of metastasis gene mediators provides new 
potential targets for treating metastatic breast cancer. The 
promise of these discoveries for translational medicine will be 
clinically evaluated in the future. Here, we discuss some of the 
foreseeable conceptual challenges of pushing these therapies 
into the clinic.
Targets for Therapy
Often times, when a patient is diagnosed with breast cancer, 
the primary tumor will be surgically removed and the residual 
disease will be eradicated by hormone, chemo, or radiation 
therapies. For patients who are at risk for developing metas-
tasis, dissemination from primary tumors occurred prior to 
diagnosis and will cease with the radical surgery. Thus, it is 
futile to target the metastasis steps that already happened, 
including intravasation, circulation, and extravasation. These 
processes will be more meaningful targets for therapy within 
the context of multiple established metastases. Via prevent-
ing metastatic lesions from cross-seeding, self-seeding, or 
re-seeding to a tertiary site,105,106 these lesions can be locally 
confined and cytotoxic therapies can be more effectively 
applied one at a time. Owing to the transient nature of these 
processes, it may also be challenging to predict their occur-
rence and to develop corresponding therapeutic strategies. 
Thus, the clinical value of identifying these targets remains 
to be demonstrated.23 A more reasonable and practical target 
for clinical intervention is cancer cell survival or proliferation. 
The current systemic therapy and its extension to the adjuvant 
setting are designed exactly for this purpose. Whether it is 
hormonal (anti-ER) therapy against ER+ breast tumors, anti-
HER2 therapy against HER2+ tumors, or chemotherapy that 
inhibits cell replication nonspecifically, all aim to sweep out 
proliferating cancer cells that remain in the patient’s body.
Lessons from Hormonal Therapy and Anti-HER2 
Therapy
Despite recognition of the distinctions between metasta-
ses and their primary tumors, metastases are treated mainly 
based on their tumors of origin. This is based on the idea that 
metastases overall behave like their tissue of origin and many 
of the primary tumor characteristics, such as growth depen-
dency and drug sensitivity, are maintained in metastases.20 
Such a notion is supported by the success of hormonal therapy 
and anti-HER2 therapy for the two breast tumor subtypes, 
respectively. Indeed, any type of cancer treatment essentially 
aims to target a sensitivity window, within which cancer cells 
are selectively killed but normal tissues are spared.107 Thus, 
the wider this window is, the higher the chance tumors will 
be effectively eliminated. Based on such reasoning, targeting 
the oncogenic signaling (in the case of anti-HER2) or the 
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lineage peculiarity of growth demand (in the case of anti-ER) 
is an optimal treatment strategy. In line with this idea, many 
emerging targeted agents against other oncogenic signaling 
or pathways that were underappreciated in breast tumorigen-
esis are now being tested in multiple clinical trials.108 These 
include inhibitors against the PI3K-Akt–mTOR pathway, 
MAPK pathway, and JAK–STAT signaling; against RTKs 
such as IGF1R, FGFR, EGFR, ERBB3, and MET; against 
integrin signaling; against cell cycle regulators such as cyclin-
dependent kinases (CDKs); and against epigenetic modifiers 
such as histone deacetylase (HDAC), DNA methyltransfer-
ase (DNMT), and bromodomain-and-extra-terminal (BET) 
domain chromatin modulators (summarized in Fig. 2). Not all 
these inhibitors are necessarily based on rationales and insights 
from metastasis biology, but in one setting or another, they are 
proven to have the ability to inhibit breast tumor growth.
However, it is also foreseeable that without considering 
the contextual specificity of distant organ environments for 
therapy, relapse and resistance may occur in many cases.109 
Drug resistance is a complicated matter of cellular intrinsic 
mechanisms for alternative activation, feedback relief,110–112 
and receiving compensatory support from the extrinsic 
microenvironment.113–115 These mechanisms lead to either 
reactivation of the suppressed oncogenic signaling or induc-
tion of a parallel pathway that supports oncogenic growth. As 
cancer cells adapt to the distant environment and metastases 
form, their growth dependence may shift away from stringent 
addiction to the oncogenic drivers of primary tumor growth. 
In the established bone metastases from breast cancer, a reper-
toire of various growth factors released from the dissolved bone 
matrix may compensate significantly for the growth stimulus 
and liberate cancer cells from reliance on the ER. As a result, 
despite the initial effectiveness of ER antagonists against ER+ 
lesions, the same therapy may become less and less effective 
as bone metastasis progresses. Indeed, in some breast cancer 
cases, even though the initial tumor is categorized as ER+, 
the resistant metastases are HER2+ or TN.83,116–118 It remains 
unclear when and how this subtype switching occur during 
tumor progression/drug intervention, but such an observation 
clearly indicates that cancer cells at a different microenviron-
ment can resort to entirely different signaling for survival and 
proliferation. The multilevels of interplay between cancer cells 
and stromal cells may render cancer cells such flexibility that 
when one proliferation signal is inhibited, another pathway 
can act on the cells and compensate. This highlights the com-
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Figure 2. a schematic shows key pathways of breast tumorigenesis and their targeted agents. 
Notes: small molecules are highlighted in light shade; antagonist antibodies are highlighted in dark shade; *indicates multitargeted inhibitors. 
Abbreviations: rtK, receptor tyrosine kinase; ai, aromatase inhibitor; serM, selective estrogen receptor modulator.
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Intratumor Heterogeneity
The metastasis cascade is depicted as a delicate process that 
requires an intricate, coordinated action of multiple gene pro-
grams. If this is true, one may expect that it should be easy to 
disrupt the cascade and inhibit metastasis by abolishing any 
gene mediator of the process. This view is largely true on a 
single-cell level. However, metastasis occurs at the level of cell 
populations. Intratumor heterogeneity that is intrinsic to most 
of the metastases renders the metastatic traits versatile, redun-
dant and complicated for targeting.
Analysis of single clones from the metastatic subpopu-
lations toward a certain organ suggests that different clones 
within the aggressive subpopulation do not necessarily 
upregulate every metastatic gene, but rather harbor different 
subsets.29,30,119 This observation suggests that there is suffi-
cient flexibility for different gene combinations to reach simi-
lar levels of metastatic fitness. In analogy to the intertumor 
heterogeneity seen in breast tumorigenesis, there exist mul-
tiple evolutionary routes for the breast tumor to reach the met-
astatic phenotype. As a result, inhibiting one mediator may 
eliminate part of metastasis but cannot eradicate it entirely. 
Denosumab, an RANKL antibody, is in clinical trials to 
revert the osteolytic cycle of breast cancer bone metastasis and 
to inhibit bone resorption.120 However, as different metastatic 
clones can foster the vicious cycle in multiple alternative ways, 
the whole population develops resistance to RANKL inhibi-
tion and a cure is rarely achieved.121
Moreover, the same genes and pathways may be repeat-
edly utilized for different purposes, functioning in a pleio-
tropic, context-dependent manner. The PI3K–Akt pathway 
is critical for cell survival in breast cancer metastasis to both 
bone and lung.54,55 However, the upstream signaling to reach 
this activation is quite distinct, with bone involving CXCL12 
and IGF1 as cytokine triggers54 and with lung involv-
ing VCAM-1-mediated interaction with macrophages.55 
VCAM-1 is important for both bone and lung metastasis from 
breast cancer.55,122 Even though VCAM-1 functions through 
different downstream mechanisms in these two settings, the 
basics of its nature remain, both through juxtacrine binding 
with leukocytes. Collectively, abolishing the metastatic traits 
requires concurrent targeting of multiple gene mediators that 
may play redundant roles and compensate each other at the 
population level.
Combination Therapy and Precision Medicine
Because of the intratumor complexity and the plasticity of 
metastases, it is expected that many of the targeted agents (Fig. 2) 
will show limited efficacies when applied singly and do not 
outperform the current standard-of-care in clinical trials.108 
An emerging concept to overcome these issues is combina-
tion therapy, which combines multiple drugs and aims to 
inhibit multiple molecular targets simultaneously. Because 
effective first-line treatments exist for ER+ and HER2+ 
breast tumors, the primary focus of combination therapy in 
these two subtypes is to overcome acquired resistance and to 
achieve enduring treatment efficacies from anti-ER and anti-
HER2 therapies. Resistance to hormonal therapy can occur 
through multiple mechanisms, including (1) reactivation of 
the ER pathway through ER mutation, ER protein modi-
fications, or modulation of the ER genome-wide binding, 
(2) upregulation of RTKs, such as EGFR, ERBB2, IGF1R, 
and FGFR, and activation of the PI3K survival signaling, or 
(3) activation of CDKs and cell proliferation via other upstream 
pathways.123–125 Resistance to anti-HER2 therapy typically 
leads to reactivation of the PI3K signaling, either through 
(1) upregulation of the ERBB2 partners EGFR/ERBB3, 
(2) loss of PTEN, or (3) mutation of the PI3K pathway com-
ponents.126 Thus, the inhibitors of these molecular targets 
are promising candidates to be included in the combination 
therapy (Fig. 2).
TN cancer, in contrast, presents a more substantial chal-
lenge. There is no targeted therapy available, and cytotoxic 
chemotherapy is the mainstay for TN tumor treatment. A spe-
cial case where targeted therapy is available is the tumors with 
BRCA mutations, which show deficiency in one arm of the 
DNA repair pathways. BRCA-mutant tumors show extraor-
dinary sensitivity to poly (ADP-ribose) polymerase (PARP) 
inhibitors and platinum chemotherapy, and can be treated 
using PARP inhibitors as single agents or in combination 
with chemotherapy. However, such therapy is not applicable 
to the majority of TN tumors, which are BRCA proficient. 
This view may be altered by an interesting finding showing 
that PI3K inhibition impairs BRCA expression and sensitizes 
BRCA wild-type tumors to PARP inhibitors in experimental 
models.127 This is further validated in some patients in a recent 
clinical trial of buparlisib and olaparib combination. Together, 
these findings demonstrate the potential of combination ther-
apy and revive the hope of many targeted agents that previ-
ously were shown to be futile as single agents.
Another layer of combination therapy is to target the 
metastasis cascade mediators and block cancer–stromal cross-
talk. Bisphosphonate and denosumab, inhibitors that block 
the osteolytic cycle, are well-known examples of drugs that 
can be combined with hormonal therapy for the treatment 
of ER+ bone metastases. Additional emerging agents of this 
category include inhibitors of WNT, NOTCH, and CXCR4 
signaling (Fig. 2), angiogenesis inhibitors, and inhibitors of 
the immune checkpoint and immune modulators. PI3K–Akt 
pathway inhibitors have gained increased interest for the TN 
subtype, partly because many of the cancer–stromal interac-
tions converge on the activation of this pathway and it controls 
metastatic survival as a central hub. Despite the many ongo-
ing clinical trials, these inhibitors have proven only margin-
ally effective as single agents. Therefore, what therapies these 
inhibitors should be combined with so that their potency could 
be leveraged becomes a major question for future research.
A fundamental challenge for combination therapy is the 
side effects that each drug carries. As the treatment potency 
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increases with the drug combination, the toxic effects to the 
host tissue also worsen. Thus, the compound effects of the 
drug toxicities significantly limit the numbers of drugs that 
can be combined as well as the dose that can be applied for 
each drug. The success of combination therapy relies on a high 
therapeutic index and requires careful design of the combina-
tion regimen.
As a result, to develop combination therapy with opti-
mal efficacy, the therapy may have to be tailored from patient 
to patient, based on a more detailed understanding and more 
comprehensive characterizations of the metastasis lesions 
for each patient. With the advent of personal genomics and 
single-cell sequencing technologies and their wider applica-
tion with patient biopsies in the clinic, precision medicine 
is no longer a farfetched idea and may be feasible in the 
future.128
Latent Metastasis
Because of the many existing challenges in targeting estab-
lished metastases, adjuvant therapy is designed to prevent 
metastasis formation, where the treatment is given after sur-
gery and before any signs of disease recurrence. This protracted 
temporal gap between the primary tumor diagnosis and the 
emergence of metastatic foci in distant organs is referred to as 
metastatic latency or metastatic dormancy (Fig. 1).129 Adju-
vant therapy is given at this time interval in an attempt to 
eradicate any microscopic lesions that escape detection and to 
minimize the risk of metastatic growth. As a result, latency is 
a temporal interplay between tumor progression and clinical 
detection/intervention.
At the cellular level, clinical latency may show as either 
solitary cancer cells or microlesions that are below the detec-
tion threshold in the clinic. These micrometastases may adopt 
a cellular state either entering quiescence or abortive growth 
with cell proliferation counterbalanced by cell death.130 Until 
now, most latent metastases in the clinic were detected in the 
form of DTCs in the bone marrow, because biopsies from 
other organs were difficult to obtain. Occasional reports of 
transmitting cancer to immunosuppressed recipients by organ 
transplantation highlight that organs beyond the bone mar-
row can harbor latent metastases as sanctuary sites.131 Detec-
tion of bone marrow DTCs in breast cancer patients has 
been shown to correlate with worsening patient prognosis 
and metastatic relapse at distant organs.132,133 However, the 
over prevalence of DTCs detected across tumor development 
stages134,135 raises the question of whether they remain rel-
evant in the occurrence of metastasis or are merely a sign of 
tumor dissemination.23
Despite the clinical importance of the dormancy state, 
few experimental models exist, leaving its biology unknown. It 
is believed that metastatic latency results from delayed adap-
tation of disseminated cancer cells to the foreign microenvi-
ronment.129 Such inadequacy may be because of cell intrinsic 
deficiencies,136,137 lack of neoangiogenic support,138,139 immune 
surveillance,140,141 or therapeutic enforcement.142,143 Adjuvant 
therapies show remarkable effectiveness in controlling ER+ 
and HER2+ breast tumors within the first five years, but a per-
sistent risk of tumor recurrence exists beyond five years.10 This 
is explained by the effectiveness of the existing adjuvant ther-
apy in targeting proliferating cells,144 but its inability to elimi-
nate the latent cells that are nonproliferating or slow cycling. 
Though this notion requires definitive proof, it prompts deeper 
thought about the targeting of latent tumor cells for improved 
metastasis prevention.145–147 The major challenge now is how to 
merge the current findings with the well-established adjuvant 
regimens.148
Even though the detailed knowledge about latent metas-
tasis is still lacking, some basic nature of these cells can be 
inferred based on the current clinical and experimental evi-
dences. First, there exist robust cell survival mechanisms that 
can support these cells during the latent period, even up to 
decades. The inability of most antimitotic therapies to eliminate 
metastases indicates that the machinery supporting latent can-
cer survival is different from that of cancer proliferation.149–151 
Cancer cells at quiescence,152,153 slowly cycling,154,155 or dis-
playing stem characteristics156 are distinct in drug sensitivity 
profiles compared to proliferating cells. Second, these latent 
cells maintain their proliferation potential and competence for 
cell cycling when the condition becomes congenial enough. 
Once they start proliferating, they may no longer depend on 
the latent survival mechanism. Thus, a drug effective against 
latent cancer cell survival may as well be futile against estab-
lished, proliferating metastases. Such a possibility may let 
these targeted agents drop off the clinical trials easily, because 
most of these agents will be first tested in the advanced cancer 
settings in breast cancer clinical trials. Systematic therapies, 
including hormonal therapy, anti-HER2 therapy, and chemo-
therapy, are approved for the adjuvant setting because of their 
demonstrated efficacies in shrinking established tumors or 
metastases. Thus, the existing therapeutic regimens set a high 
standard for the latency-targeting agents.
Even if these inhibitors can be evaluated in the adjuvant 
trials, the readout of their clinical benefits remains obscure. 
Detection of CTCs, circulating tumor DNA, or circulating 
tumor transcripts remains not yet reliable enough for infer-
ring disease progression, let alone predicting status of latent 
metastases.157 Repeated patient biopsy (for DTCs) is also too 
aggressive for merely assessing latent lesions. If the eventual 
occurrence of metastasis and patient survival serves as the end 
readout, patients may need to be monitored for more than 
10–20 years. Such long-term investments, expensive efforts, 
and high-demanding support deter the enthusiasm of phar-
maceutical companies. As a result, even though it seems quite 
appealing to target latent metastasis, many practical concerns 
impede such therapy from entering clinical testing. To over-
come these limitations, a deeper understanding of the latency 
biology and convincing preclinical evidence of such therapeu-
tic value are imperative.
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Concluding Remarks
Metastasis remains the biggest hurdle for curing breast can-
cer. Recent findings have established a conceptual framework 
of cancer metastasis and provided deeper insights on the 
molecular basis of metastatic traits, their origins, and their 
evolution. How to incorporate this knowledge into the design 
of next-generation therapy is key to combating breast cancer 
metastasis. Different challenges exist for different breast can-
cer subtypes. TN breast cancers are the most aggressive and 
metastatic, with no effective targeted therapy available. Pur-
suing more potent and more specific therapies that reduce the 
first five-year recurrence rate is needed. For ER+ and HER2+ 
tumors, even though hormonal and anti-HER2 therapies are 
effective at controlling early diseases, a persistent risk of late 
relapse and drug resistance remains. How to combat drug 
resistance via developing novel combination therapy of che-
motherapy, small molecule therapy, and immunotherapy is 
key to achieving durable therapeutic efficacies. Brain metasta-
sis becomes an increasingly manifested challenge for HER2+ 
tumors. A deeper molecular insight of organ-specific metas-
tases may guide novel therapeutic designs. To conclude, the 
past half century witnessed significant advancements in effec-
tive therapies for breast cancer, and we anticipate amazing 
breakthroughs in targeting breast cancer metastasis within 
the next 50 years.
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